Zealand Pharma is developing glepaglutide, a long-acting GLP-2 analog, as a ready-to-use, fixed-dose product for subcutaneous delivery via an auto-injector. The focus is on potential treatment for short bowel syndrome (SBS), a severe condition requiring parenteral support. Glepaglutide aims to reduce the burden of parenteral support and daily dosing for individuals with SBS, with the goal of achieving enteral autonomy. The Chief Medical Officer, David Kendall, highlights the need for more effective and convenient treatments to improve the lives of those with SBS. The company has submitted glepaglutide for regulatory review and potential approval in the US.